IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

FDA issues warning letter to RPG Life Sciences API plant in India

7:00 AM MDT | June 24, 2013 | Deepti Ramesh

FDA issued a warning letter late last month to the active pharmaceutical ingredient (API) and finished pharmaceutical manufacturing facilities of RPG Life Sciences (Mumbai)—located at Navi Mumbai and Ankleshwar, India, respectively—for violations of cGMP. The warning letter was recently published on the FDA Web site. An FDA inspections, from 28–31 January 2013 at the Navi Mumbai API facility and from 20–24 November 2012 at the Ankleshwar finished pharmaceuticals facility, identified significant deviations from cGMP for the manufacture of...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa